Compare SCM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCM | IMUX |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 209.2M |
| IPO Year | 2012 | 2013 |
| Metric | SCM | IMUX |
|---|---|---|
| Price | $7.27 | $13.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $9.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 250.7K | 149.0K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 14.22% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $117.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.83 | $0.51 |
| 52 Week High | $14.85 | $15.84 |
| Indicator | SCM | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 39.44 |
| Support Level | $6.83 | $11.21 |
| Resistance Level | $9.27 | $15.82 |
| Average True Range (ATR) | 0.34 | 0.91 |
| MACD | -0.07 | -0.29 |
| Stochastic Oscillator | 23.86 | 20.18 |
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.